BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sturm S, Lemenuel-Diot A, Patel K, Gibiansky L, Bhardwaj R, Smith PF, Dang S, Zwanziger E, Nasmyth-Miller C, Ravva P. Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization. Br J Clin Pharmacol 2021;87:1359-68. [PMID: 32808306 DOI: 10.1111/bcp.14523] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Sturm S, Lemenuel-Diot A, Patel K, Gibiansky L, Bhardwaj R, Smith PF, Dang S, Zwanziger E, Nasmyth-Miller C, Ravva P. Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization. Br J Clin Pharmacol 2021;87:1359-68. [PMID: 32808306 DOI: 10.1111/bcp.14523] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Jordie EB, Gibiansky L, Knab T, Lemenuel-Diot A, Ravva P, Zwanziger E, Jolivet S, Bhardwaj R, Hernández-Sánchez J, Nasmyth-Miller C, Sturm S. Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy. Br J Clin Pharmacol 2021. [PMID: 34449090 DOI: 10.1111/bcp.15059] [Reference Citation Analysis]
3 Pai MP, Crass RL. Translation of Pharmacodynamic Biomarkers of Antibiotic Efficacy in Specific Populations to Optimize Doses. Antibiotics (Basel) 2021;10:1368. [PMID: 34827306 DOI: 10.3390/antibiotics10111368] [Reference Citation Analysis]